Drug Profile
FAB 117-HC
Alternative Names: FAB 117; FAB 117-HC; FIB 117; NeuroSaveLatest Information Update: 15 Feb 2022
Price :
$50
*
At a glance
- Originator Ferrer Advanced Biotherapeutics; Histocell
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Spinal cord injuries
Most Recent Events
- 15 Feb 2022 Phase I/II development in Spinal cord injuries is ongoing in Spain (EudraCT2015-005717-80) (NCT02917291)
- 15 Feb 2022 Histocell announces intention to launch to FAB 117 HC for Spinal cord injuries before 2024 (Histocell pipeline, February 2022)
- 01 Dec 2016 Phase-I/II clinical trials in Spinal cord injuries in Spain (Intrathecal) (EudraCT2015-005717-80)